Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Operating Expenses: 2013-2025

Historic Operating Expenses for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to $26.4 million.

  • Theravance Biopharma's Operating Expenses fell 4.55% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.1 million, marking a year-over-year increase of 5.56%. This contributed to the annual value of $111.3 million for FY2024, which is 1.88% down from last year.
  • As of Q3 2025, Theravance Biopharma's Operating Expenses stood at $26.4 million, which was down 8.56% from $28.9 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year Operating Expenses high stood at $98.1 million for Q1 2021, and its period low was $21.6 million during Q3 2022.
  • In the last 3 years, Theravance Biopharma's Operating Expenses had a median value of $28.0 million in 2024 and averaged $28.2 million.
  • As far as peak fluctuations go, Theravance Biopharma's Operating Expenses slumped by 67.68% in 2022, and later increased by 17.43% in 2024.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Operating Expenses stood at $71.1 million in 2021, then tumbled by 54.89% to $32.1 million in 2022, then dropped by 25.80% to $23.8 million in 2023, then rose by 17.43% to $28.0 million in 2024, then decreased by 4.55% to $26.4 million in 2025.
  • Its last three reported values are $26.4 million in Q3 2025, $28.9 million for Q2 2025, and $29.8 million during Q1 2025.